|
Schwartz, Gary G (2005) Vitamin D and the epidemiology of prostate cancer. Semin Dial 18:276-89
|
|
Young, Michael V; Schwartz, Gary G; Wang, Lilin et al. (2004) The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 25:967-71
|
|
Chen, Tai C; Holick, Michael F; Lokeshwar, Bal L et al. (2003) Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res 164:273-88
|
|
Perez-Stable, Carlos M; Schwartz, Gary G; Farinas, Adan et al. (2002) The G gamma / T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089. Cancer Epidemiol Biomarkers Prev 11:555-63
|
|
Whitlatch, Lyman W; Young, Michael V; Schwartz, Gary G et al. (2002) 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol 81:135-40
|
|
Chen, T C; Schwartz, G G; Burnstein, K L et al. (2000) The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res 6:901-8
|
|
Lokeshwar, B L; Schwartz, G G; Selzer, M G et al. (1999) Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 8:241-8
|
|
Schwartz, G G; Wang, M H; Zang, M et al. (1997) 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6:727-32
|
